Clinical Trials · NCT01073865
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 222
- Start date
- Feb 2010
- Locations
- 55 sites, 6 countries
- Primary endpoint
- Number of Patients With Progression-free Survival (PFS) at 24 Weeks